Wilson NE et al., 2021-06: Randomized placebo-controlled study in healthy volunteers finding no change in complete blood counts, 41 cytokines or immune-cell gene expression after a single 0.15 mg/kg dose. It is the controlled human evidence against a short-term haematological or immune effect at the approved dose.
No significant differences were observed in complete blood counts or cytokine levels at either time point between people given ivermectin versus placebo.
Wilson NE et al., 2021-06: Randomized placebo-controlled study in healthy volunteers finding no change in complete blood counts, 41 cytokines or immune-cell gene expression after a single 0.15 mg/kg dose. It is the controlled human evidence against a short-term haematological or immune effect at the approved dose. C5 blood counts (contrary finding, recorded at full strength). Study type: randomized, placebo-controlled phase I study (ClinicalTrials.gov NCT03459794); N not stated in the abstract captured (healthy volunteers, no travel history to endemic regions); United States (University of Georgia, Athens, GA). Dose: ivermectin (Stromectol) 0.15 mg/kg orally, 3-4 tablets by weight, single dose. Comparator: placebo. Blood sampled before, 4 h and 24 h after; complete blood counts, 41 cytokines/chemokines (Luminex), 770 myeloid genes (NanoString). Declared conflicts: 'The authors declare that they have no competing interests.' Bearing CONTRADICTS the reading of the claim that ivermectin affects blood counts: at the approved dose, this trial found no short-term haematological effect. It does not address higher or prolonged dosing. Study type: randomized trial.
